GentleGen, based in Suzhou, China, recently announced the completion of a multimillion-yuan angel round of financing. This round of funding will accelerate the research and development of their automated experimental platform products and production lines, as well as the market promotion of their CRO/CDMO products, providing robust support for global life science research and the biopharmaceutical industry.
Founded in 2021, GentleGen focuses on the development of life science robotics technology and the application of artificial intelligence in life science. They provide comprehensive solutions for life science laboratories, ranging from individual scenarios to production lines. Their intelligent laboratories for gene synthesis, Sanger sequencing, and oligonucleotide synthesis are tailored to specific application scenarios. These technologies expedite research and development in areas such as gene/cell therapy, antibody drugs, and small nucleic acid drugs, while aiding in the localization of raw materials for in vitro diagnostic reagent kits.
Currently, GentleGen possesses a 3,000-square-meter intelligent laboratory and a GMP-Like production workshop, and has applied for multiple patents. They have independently designed and developed automated equipment and production lines for various scenarios.
Disclaimer: Despite our efforts to maintain accuracy, errors are unavoidable due to our limited expertise. Some information may not be up to date, and we welcome your feedback to make necessary corrections. This document is intended solely for the purpose of providing a business-oriented and written introduction to the field of synthetic biology. It does not constitute any investment advice. We appreciate your understanding.